Latest News and Press Releases

The Annual General Meeting of Hofseth BioCare ASA for 2024 will be held at the company's premises at Keiser Wilhelms gate 24, 6003 Ålesund, on 10 May 2024 at 13:00 CET. The notice of the Annual...

The Board of Directors of Hofseth BioCare ASA ("HBC") has approved the financial statements for 2023 and the Company has today published the Annual Report and Sustainability Report for 2023. Please...

Today, 5 April 2024, funds managed by Bonafide (Bonafide Global Fish Fund, Bonafide Best Catches I, HBC I, and HBC II) have purchased approx. 7.1 million shares in Hofseth BioCare ASA (“HBC”),...

Please find the HBC Company Presentation attached. For further information, please contact: James Berger, Chief Commercial Officer of Hofseth BioCare ASA Phone: +41 79 950 10 34 E-mail:...

Kristin Fjellby Grung, Chair of the Board of Hofseth BioCare ASA, has informed the Board of Directors that she will resign from the position on 31 March 2024, as she will assume a position as judge in...

HBC had gross operating revenues of NOK 47.4m (33.6m) in the fourth quarter and NOK 218.5m (120.4m) for the full year. Adjusted for the sale of assets in the second quarter, operating revenues were...

HBC Immunology Inc. (70.6% owned by Hofseth BioCare ASA) reports today the successful completion of the first in vivo study within its prostate cancer development program. The study assessed whether...

Reference is made to the stock exchange announcement on 4 January 2024 regarding the conclusion of an extraordinary general meeting in Hofseth Biocare ASA ("HBC" or the "Company") whereby the general...

Hofseth Biocare ASA ("HBC" or the "Company") has today, on 4 January 2024, completed an extraordinary general meeting. All items proposed on the agenda were adopted, including the share capital...

Reference is made to the stock exchange notice announced by Hofseth Biocare ASA ("HBC" or the "Company") on 14 December regarding the notice for an extraordinary general meeting to be held at the...